Given Imaging Announces FDA Clearance of Suspected Blood Indicator Feature

4 March 2003 - Yoqneam, Israel -- Given Imaging Ltd. (NASDAQ:GIVN), today announced that the U.S. Food and Drug Administration has cleared the Suspected Blood Indicator (SBI), a new feature of the Given Diagnostic Platform that automatically marks images that correlate with the existence of suspected blood or red areas. The SBI feature should give physicians more confidence in making a diagnosis and allow them to identify bleeding sites with greater precision during the review process.

“We have had positive experiences to date in our tests of the Suspected Blood Indicator. It has enabled us to enhance the accuracy of our diagnoses and visualize bleeding sites more clearly, “said Douglas Rex, Department of Medicine, Indiana University School of Medicine.

“Given Imaging continues to innovate and bring to market diagnostic solutions to the GI community,” said Gavriel D. Meron, president and CEO of Given Imaging Ltd.

Current Given Imaging customers with systems under warranty or service contract will receive their RAPID 2.0 SBI upgrades within the next 60 days.

This press release contains forward-looking statements about Given Imaging, including projections about our business, our future revenues, and our future profitability, within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. For example, statements in the future tense, words such as "anticipates," "estimates," "expects," "intends," "plans," "believes," and words and terms of similar substance used in connection with any discussion of future operating or financial performance identify such forward-looking statements. Those forward-looking statements are not guarantees of future performance and actual results could differ materially from our current expectations as a result of numerous factors, including but not limited to the following: changes in regulatory environment, our success in implementing our sales, marketing and manufacturing plan, protection and validity of patents and other intellectual property rights, the impact of currency exchange rates, the effect of competition by other companies, the outcome of future litigation, the reimbursement policies for our product from healthcare payors, quarterly variations in operating results, the possibility of armed conflict or civil or military unrest in Israel and other risks disclosed in our filings with the U.S. Securities Exchange Commission.

19.Sept.'03